Regeneron Pharmaceuticals

Regeneron Announces Investor Conference Presentation

Retrieved on: 
Wednesday, November 15, 2023
Regeneron Pharmaceuticals, Webcast, Conference, Pharmaceutical industry

TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Key Points: 
  • TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
    Piper Sandler 35th Annual Healthcare Conference at 8:30 a.m.
  • ET on Tuesday, November 28, 2023
    The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations .
  • A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Retrieved on: 
Tuesday, November 14, 2023
Regeneron Pharmaceuticals, Osteoporosis, Research, Albany Medical College, UCB, Osteoarthritis, Disease, Tissue, Clinical trial, Teaching hospital, Internal medicine, Patient, Bristol Myers Squibb, Reiko True, AbbVie, Arthritis, Joint, Rheumatology, Health, Abstract, North Shore University Hospital, Pain, Janssen, APG system, Rheumatism, Confusion, GSK plc, HIV disease progression rates, Inflammation, Amgen, Cryptocurrency, Pharmaceutical industry, Pfizer, Rheumatoid arthritis, Takeda, Genentech

is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

Key Points: 
  • is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.
  • The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Controlled, Randomized study, examining Natrunix in combination with methotrexate for the treatment of Rheumatoid Arthritis.
  • I am excited to be part of a clinical trial program studying a novel approach to RA.”
    Dr. Kivitz has had a prodigious medical career treating arthritis and rheumatic diseases.
  • Dr. Kivitz has authored over 500 research articles, abstracts, and clinical studies relating to osteoarthritis, osteoporosis and rheumatoid arthritis and has lectured on his findings around the world.

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Retrieved on: 
Monday, November 13, 2023
Together for Change, Meharry Medical College, Research, STEM, Engineering, Science education, Science News, Mathematics, Canadian International Council, STS, Disease, Regeneron Science Talent Search, Student, Ecosystem, Chairperson, ISEF, News, Partnership, Female, Education, Pharmaceutical industry, Management, Science, Regeneron Pharmaceuticals, Society

TARRYTOWN, N.Y. and WASHINGTON, D.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (Society) today announced that Regeneron is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period.

Key Points: 
  • Each year, over 175,000 students compete in the Society's 400 affiliated high school science fairs around the world.
  • Top winners earn the right to compete at Regeneron ISEF where nearly 1,600 finalists, half of whom are young female scientists, are judged in 22 different categories.
  • The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition.
  • These high school science competitions play a pivotal role in directing high school students towards STEM careers.

Global CD3 Antibodies Market, Dosage, Price, & Sales Report 2023-2028: $5 Billion Opportunity, Clinical Trials Insights on 250 Antibodies, and 9 Commercially Approved CD3 Antibodies - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Uveal melanoma, Multiple myeloma, Indication, AstraZeneca, EMA, Leukemia, Catumaxomab, CD19, FDA, Acute lymphoblastic leukemia, Regeneron Pharmaceuticals, Cancer, Clinical trial, Muromonab-CD3, Antibody, CD3, Lymphoma, Amgen, Generic drug, Vaccine, Blinatumomab

The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market.
  • Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market.
  • Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
    Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028
    CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

For Private and Small-Cap Public Life Sciences Companies, Biotech Showcase™ to Set the Tone for the Industry in 2024

Retrieved on: 
Thursday, December 14, 2023
Health, Technology, Neurology, Other Health, Software, Pharmaceutical, Biotechnology, Therapy, Investment, Scientific American, Conference, Regeneron Pharmaceuticals, Drug discovery, Astellas Pharma, Khosla Ventures, Novo Nordisk

Demy-Colton and EBD Group ’s Biotech Showcase ™ opens in conjunction with JPM Week, January 8-10, 2024 in San Francisco.

Key Points: 
  • Demy-Colton and EBD Group ’s Biotech Showcase ™ opens in conjunction with JPM Week, January 8-10, 2024 in San Francisco.
  • Held at the Hilton San Francisco Union Square, Biotech Showcase™ focuses on how the biopharma industry can accelerate drug discovery and what’s hot in therapeutics development.
  • They join more than 1,300 investors, more than 70 members of the news media, and upwards of 340 public and private presenting companies across biotechnology and digital healthcare.
  • Conference registration provides attendees access to the full Biotech Showcase™ program, encompassing specialized events such as the DigiMed Showcase and Seed Showcase.

OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas

Retrieved on: 
Monday, November 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Micelle, Stimulator of interferon genes, Clinical trial, Polymer, Patient, Regeneron Pharmaceuticals, University, Cancer, Lymphoma, Nucleic acid metabolism, UPMC, Vaccine

The ONM-501 trial ( NCT06022029 ) is a multicenter Phase 1, dose escalation and dose expansion study in patients with advanced solid tumors and lymphomas.

Key Points: 
  • The ONM-501 trial ( NCT06022029 ) is a multicenter Phase 1, dose escalation and dose expansion study in patients with advanced solid tumors and lymphomas.
  • ONM-501 features dual STING activation, with the polymers used to construct the micelles binding to and activating STING alongside the payload critical to activation.
  • During the combinatorial dose escalation and expansion cohort segments of the trial, ONM-501 will be dosed in combination with Regeneron’s Libtayo® (cemiplimab-rwlc), an anti-PD-1 monoclonal antibody.
  • OncoNano and Regeneron have entered into a clinical trial supply agreement for this ONM-501 study.

Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, PD-L1, Clinical trial, CSCC, PD-1, Neoplasm, Skin, Patient, Tumor microenvironment, Therapy, Toxicity, Pharmaceutical industry, Regeneron Pharmaceuticals

Ankyra Therapeutics, a clinical stage biotechnology company developing a new form of local immunotherapy termed “anchored immunotherapy,” today announced a clinical trial supply agreement with Regeneron to evaluate ANK-101 in combination with Regeneron’s anti-PD-1 therapy, Libtayo® (cemiplimab).

Key Points: 
  • Ankyra Therapeutics, a clinical stage biotechnology company developing a new form of local immunotherapy termed “anchored immunotherapy,” today announced a clinical trial supply agreement with Regeneron to evaluate ANK-101 in combination with Regeneron’s anti-PD-1 therapy, Libtayo® (cemiplimab).
  • The Ankyra platform uses an inert aluminum hydroxide scaffolding to link to bioactive immuno-oncology agents.
  • Significant monotherapy anti-tumor activity has been seen in multiple murine tumor models and in a Phase I clinical trial of canine melanoma.
  • “We are excited to expand our clinical collaborations to evaluate the combination of ANK-101 with cemiplimab in cutaneous squamous cell carcinoma (CSCC),” said Dr. Joe Elassal, Chief Medical Officer at Ankyra.

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Pharmaceutical, Health, Other Health, NDA, Apoptosis, Interleukin 5, AstraZeneca, Neutrophil, Ageing, CH2, Skin, B cell, Clinical trial, Sanofi, Basophil, Macrophage, Patient, FDA, Mergers and acquisitions, Benralizumab, New Drug Application, Therapy, Atopic dermatitis, Regeneron Pharmaceuticals, Drug discovery, Eosinophil, Discovery, News, Dupilumab, Pharmaceutical industry, Vaccine, Health care, Skin condition, Bullous pemphigoid, Phase

The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.

Key Points: 
  • The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.
  • It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape.
  • Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

Analysis Group Researchers Evaluated Long-Term Patient Experience with Dupilumab Using Groundbreaking Method for Generating Real-World Data

Retrieved on: 
Tuesday, December 12, 2023
Regeneron Pharmaceuticals, JAMA Dermatology, Analysis Group, Atopic dermatitis, LEAP, Physician, Gold, Pros, Clinical trial, Yale school, RWD, Sinusitis, Harvard Medical School, Polyp (medicine), Yale School of Medicine, Area studies, JAMA, Nursing, Pharmaceutical industry, Sanofi, Dermatology, Patient

The study, published in the journal Dermatology and Therapy , extends the one-year results of the previously published RELIEVE-AD study in JAMA Dermatology , which was based on a groundbreaking method for generating real-world data (RWD).

Key Points: 
  • The study, published in the journal Dermatology and Therapy , extends the one-year results of the previously published RELIEVE-AD study in JAMA Dermatology , which was based on a groundbreaking method for generating real-world data (RWD).
  • This approach provides a true baseline against which to compare longitudinal data over time.
  • "Generating real-world data is particularly challenging for conditions like atopic dermatitis that require long-term therapy extending beyond the initial study period.
  • "Leveraging manufacturers' programs, such as patient support programs, has proven to be a breakthrough solution for generating early and long-term high-quality RWD."

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting

Retrieved on: 
Monday, December 4, 2023
Acquisition, Therapy, ASH, CLEC2D, Immunoglobulin G, Biotechnology, Patient, Neoplasm, Checkmate, Hematology, Regeneron Pharmaceuticals, TLR9, Cancer, SITC, CMO, Bone marrow, Society, CD161, DSM-IV codes, Biology, NK, Drug development, Pharmaceutical industry, Vaccine

WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO). The company also announced it will present new data supporting continued clinical development of its lead program IMT-009 for solid tumors and hematological malignancies at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023).

Key Points: 
  • Seasoned biotech executive James Wooldridge, M.D., named Chief Medical Officer to support advancement of immuno-oncology pipeline
    WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of James Wooldridge, M.D., as Chief Medical Officer (CMO).
  • Dr. Wooldridge has served as Acting CMO since June 2023 and has been an advisor to the Company since October 2022.
  • "We are pleased to announce Jim's appointment as our Chief Medical Officer as we continue progressing toward our goal of providing groundbreaking therapeutic solutions for patients with cancer," said Amanda Wagner, Chief Executive Officer of Immunitas.
  • He previously served as the Chief Medical Officer at Checkmate Pharmaceuticals leading up to the company's acquisition by Regeneron.